Evaluation of STAT3 rs1053004 single nucleotide polymorphism in patients with chronic hepatitis B and hepatocellular carcinoma.

Evaluation of STAT3 rs1053004 single nucleotide polymorphism in patients with chronic hepatitis B and hepatocellular carcinoma. Cell Mol Biol (Noisy-le-grand). 2017 Dec 30;63(12):45-50 Authors: Fatemipour M, Arabzadeh SAM, Molaei H, Geramizadeh B, Dabiri S, Fatemipour B, Vahedi SM, Malekpour Afshar R Abstract Chronic infection with hepatitis B (CHB) virus is one of the most important risk factors for Hepatocellular carcinoma (HCC). Hepatitis B virus (HBV) causes liver cancer in various ways. One of these ways is increasing the expression of the signal transducer and activator of transcription 3 (STAT3) in Hepatocytes by HBV. The purpose of this research is to evaluate the single nucleotide polymorphism (SNP) rs1053004 in the STAT3 gene in CHB patients and individuals who suffer from HCC. In this research, 33 patients CHB-related HCC, 50 patients infected with chronic hepatitis B infection (CHB) without HCC and 50 healthy individuals were investigated for the presence of rs1053004 in the STAT3 gene according to the PCR-based differentiation of alleles test. Data analysis presented a different and significant distribution of alleles and genotypes (p<0.05). When the HCC and CHB groups were compared from the point of the frequency of alleles, the frequency of the C allele and CC genotype in the HCC group were higher CHB and control groups. Analysis of our data in the genotype model (CC vs. TT + TC) showed, this meaningful relationship remained between the ...
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Related Links:

Hepatocellular carcinoma is one of the main consequences of liver chronic disease. Hepatocellular carcinoma-related changes may be seen in patients with chronic hepatitis B. The aim of the current study was to quantitate liver tissue elements by stereological technique in patients with hepatitis B-related cancer and compare the results with control and only hepatitis B group. Needle liver biopsies from 40 patients with only chronic hepatitis B infection, from 41 patients with only early hepatocellular carcinoma, from 40 patients with early hepatitis B-related cancer and 30 healthy subjects (control group) were analyzed by ...
Source: European Journal of Histochemistry - Category: Biomedical Science Source Type: research
Authors: Wu D, Liang H, Wang H, Duan C, Yazdani H, Zhou J, Pan Y, Shan B, Su Z, Wei J, Cui T, Tai S Abstract Hepatitis B virus (HBV) infection is a risk factor for hepatocellular carcinoma (HCC). HBV X protein (HBx) is an important carcinogen for HBV-induced HCC. When the HBx gene is integrated into the host cell genome, it is difficult to eradicate. The identification of an effective target to inhibit the oncogenic function of HBx is therefore critically important. The present study demonstrated that HBx, particularly truncated HBx, was expressed in several HBV-derived cell lines (e.g., Hep3B and SNU423). By analy...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Aflatoxin B1 (AFB1) is currently the most commonly studied mycotoxin due to its great toxicity, its distribution in a wide variety of foods such as grains and cereals and its involvement in the development of  + (HCC). HCC is one of the main types of liver cancer, and has become a serious public health problem, due to its high incidence mainly in Southeast Asia and Africa. Studies show that AFB1 acts in synergy with other risk factors such as hepatitis B and C virus (HBV and HCV) leading to the devel opment of HCC through genetic and epigenetic modifications.
Source: Translational Research - Category: Research Authors: Source Type: research
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide and the second cause of cancer-related deaths.[1] The vast majority of cases develop in patients with chronic liver diseases, the main risk factors being Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infection, alcohol intake and metabolic syndrome.[2,3] Clinical outcome remains poor, with approximately only one third of patients eligible to potentially curative treatments such as surgical resection, radiofrequency ablation or liver transplantation.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Conclusion: Low ZAP expression is closely associated with disease progression and poor prognosis for patients with HCC.Cell Physiol Biochem 2018;49:1048 –1059
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Authors: Di Bisceglie AM Abstract Chronic viral hepatitis types B and C may eventually lead to the development of hepatocellular carcinoma. Although hepatitis B is readily preventable by vaccination, there is growing evidence that antiviral therapy directed against hepatitis B may reduce the risk of liver cancer among those already infected. There is no vaccine against hepatitis C, but the evidence is now strong that antiviral therapy with sustained virological response (viral cure) reduces, but does not eliminate, the risk of hepatocellular carcinoma. PMID: 30182913 [PubMed - in process]
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
Authors: Zakharia K, Luther CA, Alsabbak H, Roberts LR Abstract Hepatocellular carcinoma (HCC) originates from hepatocytes usually secondary to chronic inflammation and cirrhosis. It is an important disease of global significance with a high incidence and mortality. It is the fifth and eighth most common cancer in males and females, respectively. HCC is also extremely lethal; in 2015 it was the second and sixth most common cause of death from cancer in males and females, respectively. Chronic viral hepatitis B and C are the most frequent risk factors for the development of HCC, and the global distribution of HCC la...
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
It is unclear whether elevated fasting serum glucose level and type 2 diabetes (T2DM) are associated with an increased risk of hepatocellular carcinoma (HCC), irrespective of obesity in patients with chronic hepatitis B.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
ConclusionsIL-37b inhibits HCC growth, metastasis and epithelial mesenchymal transition by regulating IL-6/STAT3 signaling. Serum IL-37b may be a biomarker for HBV-HCC and its staging.
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
Conclusion: The results of the natural history of individuals with chronic hepatitis B phases CHB shows immune tolerance (7%), eAg+ Immune Clearance (19.7%), eAg- Immune Clearance (40.84%) and Inactive Carrier (32.39%). To prevent the consequence of CHB infection, an individual in immune tolerance phase should be tested periodically for ALT level, HBV markers, HBsAg, HBcIgG, HBeAg, HBeAb and HBV viral load. Then decision-making therapy can be applied for CHB patients at early stage of immune clearance. PMID: 30139211 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Carcinoma | Genetics | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Iran Health | Liver | Liver Cancer | Middle East Health | Molecular Biology | Urology & Nephrology